Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. More Details
Undervalued with adequate balance sheet.
Share Price & News
How has Supernus Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SUPN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: SUPN's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: SUPN exceeded the US Pharmaceuticals industry which returned 13.3% over the past year.
Return vs Market: SUPN underperformed the US Market which returned 33% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Supernus Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StIs Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 49% Discount?
1 month ago | Simply Wall StSupernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
2 months ago | Simply Wall StSupernus Pharmaceuticals (NASDAQ:SUPN) Seems To Use Debt Rather Sparingly
Is Supernus Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SUPN ($27.26) is trading below our estimate of fair value ($51.68)
Significantly Below Fair Value: SUPN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SUPN is good value based on its PE Ratio (14.5x) compared to the US Pharmaceuticals industry average (22.6x).
PE vs Market: SUPN is good value based on its PE Ratio (14.5x) compared to the US market (17.5x).
Price to Earnings Growth Ratio
PEG Ratio: SUPN is poor value based on its PEG Ratio (1.2x)
Price to Book Ratio
PB vs Industry: SUPN is good value based on its PB Ratio (1.8x) compared to the US Pharmaceuticals industry average (3.1x).
How is Supernus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SUPN's forecast earnings growth (11.6% per year) is above the savings rate (2%).
Earnings vs Market: SUPN's earnings (11.6% per year) are forecast to grow slower than the US market (14.9% per year).
High Growth Earnings: SUPN's earnings are forecast to grow, but not significantly.
Revenue vs Market: SUPN's revenue (1.8% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: SUPN's revenue (1.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SUPN's Return on Equity is forecast to be high in 3 years time
How has Supernus Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SUPN has high quality earnings.
Growing Profit Margin: SUPN's current net profit margins (17.5%) are lower than last year (27.9%).
Past Earnings Growth Analysis
Earnings Trend: SUPN's earnings have grown by 12.1% per year over the past 5 years.
Accelerating Growth: SUPN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SUPN had negative earnings growth (-15.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.5%).
Return on Equity
High ROE: SUPN's Return on Equity (12.8%) is considered low.
How is Supernus Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: SUPN's short term assets ($639.2M) exceed its short term liabilities ($283.4M).
Long Term Liabilities: SUPN's short term assets ($639.2M) exceed its long term liabilities ($504.0M).
Debt to Equity History and Analysis
Debt Level: SUPN's debt to equity ratio (47.1%) is considered high.
Reducing Debt: SUPN's debt to equity ratio has increased from 5.1% to 47.1% over the past 5 years.
Debt Coverage: SUPN's debt is well covered by operating cash flow (32.4%).
Interest Coverage: SUPN's interest payments on its debt are well covered by EBIT (8.1x coverage).
What is Supernus Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SUPN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SUPN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SUPN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SUPN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SUPN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jack Khattar (60 yo)
Mr. Jack A. Khattar founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as its Chief Executive Officer, President, Secretary and Director since 2005. From 199...
CEO Compensation Analysis
Compensation vs Market: Jack's total compensation ($USD6.67M) is above average for companies of similar size in the US market ($USD3.70M).
Compensation vs Earnings: Jack's compensation has been consistent with company performance over the past year.
Experienced Management: SUPN's management team is seasoned and experienced (6.2 years average tenure).
Experienced Board: SUPN's board of directors are considered experienced (8.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Supernus Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Supernus Pharmaceuticals, Inc.
- Ticker: SUPN
- Exchange: NasdaqGM
- Founded: 2005
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.449b
- Shares outstanding: 53.15m
- Website: https://www.supernus.com
Number of Employees
- Supernus Pharmaceuticals, Inc.
- 9715 Key West Avenue
- United States
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its comm...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 00:13|
|End of Day Share Price||2021/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.